Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02764333 · ClinicalTrials.gov registry record · Phase 2
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT02764333 is a Phase 2 study of Ovarian Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 29 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT02764333, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 2 clinical trial, which tests two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF, and durvalumab (MEDI4736) , which is an antibody drug that help un-block parts of the immune system. The aim of this study is to find out whether these drugs, when given together are safe, and whether they are effective in treating cancer.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL TPIV200
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center @ Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center at Rockville - Rockville Centre
New Jersey
- Memorial Sloan Kettering Cancer Center at Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-05-06 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02764333
The ClinicalTrials.gov registry entry for NCT02764333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT02764333 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02764333 about?
NCT02764333 is a clinical study titled "TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer". This is a Phase 2 clinical trial, which tests two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF, and durvalumab (MEDI4736) , which is an antibody drug that help un-block parts of the immune syst...
What is the current status of trial NCT02764333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-05-06. Estimated completion is 2021-01-20.
What conditions does trial NCT02764333 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT02764333?
The interventions under investigation include: Durvalumab (BIOLOGICAL), TPIV200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02764333?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02764333 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.